Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 4
1993 3
1994 4
1995 8
1996 6
1997 5
1998 13
1999 27
2000 42
2001 41
2002 72
2003 83
2004 70
2005 91
2006 74
2007 72
2008 89
2009 63
2010 69
2011 71
2012 91
2013 75
2014 83
2015 70
2016 77
2017 57
2018 52
2019 59
2020 66
2021 56
2022 65
2023 51
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

1,586 results

Results by year

Filters applied: . Clear all
Page 1
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E, Toumi H. Lespessailles E, et al. Int J Mol Sci. 2022 Sep 14;23(18):10733. doi: 10.3390/ijms231810733. Int J Mol Sci. 2022. PMID: 36142643 Free PMC article. Review.
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole). Recently, the risks and benefits of long-term PPI use were questioned and many studies indicated that their use should …
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and …
Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Ochoa D, Román M, Cabaleiro T, Saiz-Rodríguez M, Mejía G, Abad-Santos F. Ochoa D, et al. BMC Pharmacol Toxicol. 2020 Jul 25;21(1):54. doi: 10.1186/s40360-020-00433-2. BMC Pharmacol Toxicol. 2020. PMID: 32711578 Free PMC article. Clinical Trial.
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials. METHOD: Subjects were evaluated to determine the …
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study popu …
Pharmacological treatment of gastro-oesophageal reflux in children.
Tighe MP, Andrews E, Liddicoat I, Afzal NA, Hayen A, Beattie RM. Tighe MP, et al. Cochrane Database Syst Rev. 2023 Aug 22;8(8):CD008550. doi: 10.1002/14651858.CD008550.pub3. Cochrane Database Syst Rev. 2023. PMID: 37635269 Review.
Children Proton pump inhibitors (PPIs) at different doses may provide little to no symptomatic and endoscopic benefit. Rabeprazole given at different doses (0.5 mg/kg and 1 mg/kg) may provide similar symptom improvement (127 children in total; very low-certainty evidence). …
Children Proton pump inhibitors (PPIs) at different doses may provide little to no symptomatic and endoscopic benefit. Rabeprazole gi …
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Sakurai Y, et al. Aliment Pharmacol Ther. 2015 Sep;42(6):719-30. doi: 10.1111/apt.13325. Epub 2015 Jul 21. Aliment Pharmacol Ther. 2015. PMID: 26193978 Free article. Clinical Trial.
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabeprazole 10 mg (Study V vs. R) were orally administered daily for 7 days. ...RESULTS: Acid-inhibitory effect (pH4 HTR) of vonoprazan was sign …
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabepraz
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ, Andersson TB, Ahlström M, Weidolf L. Li XQ, et al. Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821. Drug Metab Dispos. 2004. PMID: 15258107
., omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) as inhibitors of four cytochrome P450 enzymes (CYP2C9, 2C19, 2D6, and 3A4), we performed in vitro studies using human liver microsomal preparations and recombinant CYP2C19. ...The inhibitory potency …
., omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) as inhibitors of four cytochrome P450 enzymes (CYP2C9, 2C19 …
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazole …
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time …
Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY, Zhou L, Hu YL, Ding XW, Long H, Liu F, Xu M, Zhang ZY, Li SL, Wang QY, Su CX, Chen Y, Chen J, Lin Y, Li PY. Han YY, et al. J Gastroenterol. 2023 Dec;58(12):1167-1177. doi: 10.1007/s00535-023-02042-2. Epub 2023 Oct 1. J Gastroenterol. 2023. PMID: 37777987 Clinical Trial.
This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dual therapy, and to provide a more efficient, safer, and convenient dual regimen for H. pylori infection. ...The participants were randomly as …
This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dua …
Rabeprazole: A comprehensive profile.
Bakheit AH, Al-Kahtani HM, Albraiki S. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:137-183. doi: 10.1016/bs.podrm.2020.07.003. Epub 2020 Aug 13. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461697
Rabeprazole belongs to the class of anti-secretory drugs, with benzimidazoles substitution. ...This effect helps to treat and prevent conditions in which gastric acid directly aggravates symptoms such as duodenal and gastric ulcers. This chapter includes a comprehensive re
Rabeprazole belongs to the class of anti-secretory drugs, with benzimidazoles substitution. ...This effect helps to treat and prevent
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash RP, Rais R, Srinivas NR. Dash RP, et al. Xenobiotica. 2018 Apr;48(4):422-432. doi: 10.1080/00498254.2017.1307470. Epub 2017 Apr 6. Xenobiotica. 2018. PMID: 28294690 Review.
One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition. 4. The review was aimed to provide pharmacokinetic data of rabeprazole from several clinical studies including d …
One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmaco …
Review article: the pharmacology of rabeprazole.
Williams MP, Pounder RE. Williams MP, et al. Aliment Pharmacol Ther. 1999 Aug;13 Suppl 3:3-10. doi: 10.1046/j.1365-2036.1999.00019.x. Aliment Pharmacol Ther. 1999. PMID: 10491723 Free article. Review.
Rabeprazole sodium is a new substituted benzimidazole proton pump inhibitor with several differences compared with existing proton pump inhibitors. ...This probably reflects rabeprazole's faster activation in the parietal cell canaliculus. In human studies, once-dai
Rabeprazole sodium is a new substituted benzimidazole proton pump inhibitor with several differences compared with existing proton pu
1,586 results